Alizyme has a late stage, diversified portfolio of competitive products for the treatment of obesity and type 2 diabetes, ulcerative colitis and mucositis.

Share Price

19 Nov 08
London Stock Exchange

12.00 GBp

Change -2.00

(20 minutes delayed)


Corporate Presentations

24/07/08
COLAL-PRED®Phase III Clinical Trial Presentation

24/07/08
Replay of the webcast of the Analyst Meeting announcing the results of its European Phase III clinical trial of COLAL-PRED® , which took place at 11:00am (GMT) on Thursday 24th July 2008.

Latest News

16/09/08
Takeda Milestone Payment

05/09/08
Update on Board Change

29/08/08
Interim Results for the six months ended 30 June 2008

29/08/08
Interim Report 2008

09/04/08
Annual Report & Accounts 2007